<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="394">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04187547</url>
  </required_header>
  <id_info>
    <org_study_id>AC-19-020</org_study_id>
    <nct_id>NCT04187547</nct_id>
  </id_info>
  <brief_title>A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension</brief_title>
  <official_title>A Phase III, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Subjects With Mild to Moderately Severe Probable Alzheimer's Disease and Who Are Noncarriers of the APOE4 Allele</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerecin</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerecin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is Phase 3 study, multi-centre, double-blind, placebo controlled, parallel group to&#xD;
      evaluate the effects of AC-SD-03 on the efficacy and safety among participants with mild to&#xD;
      moderate Alzheimer's Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2022</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11). Total Score up to 20-week Treatment</measure>
    <time_frame>20 weeks</time_frame>
    <description>Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog 11) is an 11- item cognitive subscale that objectively measures memory, language, orientation, and praxis with a total score range of 0 (no impairment) to 70 (severe impairment).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment related adverse events</measure>
    <time_frame>20 weeks</time_frame>
    <description>TEAE incidence rate per treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change</measure>
    <time_frame>20 weeks</time_frame>
    <description>Clinician's global impression rated with Alzheimer's Disease cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dependence Scale.Total Score up to 20-week Treatment</measure>
    <time_frame>20 weeks</time_frame>
    <description>The Dependence Scale is a 13-item scale with a total score from 0 to 15, where higher scores indicate more dependence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in RUD-Lite</measure>
    <time_frame>20 weeks</time_frame>
    <description>The RUD-lite is an interview designed to assess resource utilisation required for subjects with dementia and their caregivers. Information gathered on both caregivers (caregiving time, work status) and participants (accommodation and healthcare resource utilization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disability Assessment for Dementia</measure>
    <time_frame>20 weeks</time_frame>
    <description>The Disability Assessment for Dementia (DAD) is an interview designed to measure of functional ability in dementia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">344</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>AC-SD-03</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tricaprilin SD formulation, twice daily. Administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-SD-03P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo formulation, twice daily. Administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tricaprilin</intervention_name>
    <description>Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.&#xD;
Each dosing unit of AC-SD-03 contains 20 g of the active ingredients (tricaprilin)</description>
    <arm_group_label>AC-SD-03</arm_group_label>
    <other_name>AC-SD-03</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.</description>
    <arm_group_label>AC-SD-03P</arm_group_label>
    <other_name>AC-SD-03P</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects between the ages of 50 and 85 (inclusive) at the time of Screening Visit 1.&#xD;
             Subjects 86 to 90 years of age (inclusive) can be enrolled, provided that the Medical&#xD;
             Monitor reviews the subject's medical condition during the screening process and&#xD;
             approves enrolment.&#xD;
&#xD;
          2. Dementia of mild to moderate severity, as classified by MMSE score between 14 to 26,&#xD;
             inclusive, at Screening Visit 1.&#xD;
&#xD;
          3. Meets diagnostic clinical criteria of probable Alzheimer's dementia according to the&#xD;
             National Institute on Aging and the Alzheimer's Association (NIA-AA) [25].&#xD;
&#xD;
          4. Magnetic resonance imaging prior to Visit 3 (Baseline) compatible with a diagnosis of&#xD;
             probable AD.&#xD;
&#xD;
          5. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) brain scan showing a pattern&#xD;
             typical for AD according to central PET reader (with areas of glucose hypometabolism&#xD;
             in posterior cingulate, temporal, parietal, and/or prefrontal cortices, as per&#xD;
             criteria in imaging manual).&#xD;
&#xD;
          6. Confirmed APOE negative genotype result obtained by the central laboratory prior to&#xD;
             Screening Visit 2 or documented prior to screening.&#xD;
&#xD;
          7. Subjects taking the following cholinesterase inhibitors (ChEI): donepezil,&#xD;
             galantamine, or rivastigmine; and/or GV-971, and/or memantine and/or other agents&#xD;
             which may impact cognition (e.g., Souvenaid®, NeuroAidTM, Cerefolin®, Gingko biloba,&#xD;
             etc) are eligible for enrolment:&#xD;
&#xD;
               1. If the subject has been taking such medication(s)/products for 3 months or more&#xD;
                  at Screening Visit 1.&#xD;
&#xD;
               2. If the current dosage regimen is within the approved dose range.&#xD;
&#xD;
               3. The daily dose has remained unchanged for at least 6 weeks prior to screening.&#xD;
&#xD;
               4. If the dose is not expected to change during trial participation.&#xD;
&#xD;
               5. Tacrine use is not allowed.&#xD;
&#xD;
          8. In the opinion of the Investigator, the subject's medical condition, except for&#xD;
             dementia, has been stable for at least 3 consecutive months prior to Screening Visit&#xD;
             1.&#xD;
&#xD;
          9. Subjects do not have active suicidal thoughts (answers 'yes' to questions 4 or 5, on&#xD;
             the Columbia-Suicide Severity Rating Scale [C-SSRS]) within 6 months preceding&#xD;
             Screening Visit 2 or Visit 3 (Baseline). Additionally, subjects have no active history&#xD;
             of suicide attempt in the previous 2 years or more than 1 lifetime suicide attempt,&#xD;
             nor are they at serious suicidal risk, in the opinion of the Investigator.&#xD;
&#xD;
         10. The subject is able to comply with protocol testing and procedures for the entire&#xD;
             length of the trial.&#xD;
&#xD;
         11. Has a permanent caregiver (subject's caregiver is not expected to change during the&#xD;
             trial) who is willing to attend all visits, oversee the subject's compliance with&#xD;
             protocol-specified procedures and IP administration, and report on subject's status.&#xD;
             Caregiver must have, in the opinion of the Investigator, enough contact with the&#xD;
             subject to be able to perform the duties described above.&#xD;
&#xD;
         12. The subject and caregiver are, in the Investigator's judgement, proficient in the&#xD;
             language in which the trial assessments will be completed, and have hearing, vision&#xD;
             and physical abilities adequate to perform assessments (corrective aids allowed).&#xD;
&#xD;
         13. Subject and caregiver must provide full written informed consent prior to the&#xD;
             performance of any protocol-specified procedure; or if subject is unable to provide&#xD;
             informed consent due to cognitive status, provision of informed consent by cognitively&#xD;
             intact legally acceptable representative (where this is in accordance with local laws,&#xD;
             regulations and ethics committee policy).&#xD;
&#xD;
         14. Subject is able to ingest oral medication.&#xD;
&#xD;
         15. Subject is able to tolerate a 5 g dose of tricaprilin (formulated as 12.5 g of&#xD;
             AC-SD-03) as per sentinel dose challenge at Visit 3 (Baseline).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current use or use within 3 months of Visit 3 (Baseline), of Axona® or other&#xD;
             MCT-containing products. Use of coconut oil up to 15 mL (1 tablespoon) per day is&#xD;
             allowed. Use of MCT-containing products is not allowed at any time during trial&#xD;
             participation.&#xD;
&#xD;
          2. Use of any other investigational agent within 60 days prior to Screening Visit 1.&#xD;
&#xD;
          3. Has a known allergy or hypersensitivity to triglycerides.&#xD;
&#xD;
          4. In the opinion of the Investigator, has presence or history of an advanced, severe,&#xD;
             progressive, or unstable disease of any type that could interfere with efficacy and&#xD;
             safety assessments, or put the subject at risk.&#xD;
&#xD;
          5. Has any medical or neurological condition, other than AD, that could explain the&#xD;
             subject's dementia (e.g., structural abnormality, traumatic brain injury, stroke,&#xD;
             epilepsy, Parkinson's disease, alcohol-related dementia, etc.)&#xD;
&#xD;
          6. Has a modified Hachinski Ischemia score greater than (&gt;) 4 at Screening Visit 2.&#xD;
&#xD;
          7. Has a history or clinical laboratory evidence of cerebrovascular disease (stroke,&#xD;
             transient ischemic attack, haemorrhage), or diagnosis of possible, probable, or&#xD;
             definite vascular dementia at Screening Visit 1 in accordance with National Institute&#xD;
             of Neurological Disorders and Stroke criteria.&#xD;
&#xD;
          8. Brain MRI performed at Screening (prior to Visit 3) (per centrally read MRI) that&#xD;
             shows evidence of any of the following:&#xD;
&#xD;
               1. Acute, sub-acute or chronic haemorrhage.&#xD;
&#xD;
               2. Cortical infarct (defined as &gt; 1.5 cm in diameter).&#xD;
&#xD;
               3. &gt; 1 lacunar infarct (defined as &lt; 1.5 cm in diameter).&#xD;
&#xD;
               4. Superficial siderosis.&#xD;
&#xD;
               5. History of diffuse white matter disease as defined by a score of 3 on the&#xD;
                  age-related white matter changes scale [26].&#xD;
&#xD;
               6. Any finding that, in the opinion of the Investigator, might be a contributing&#xD;
                  cause of subject's dementia, might pose a risk to the subject, or might prevent a&#xD;
                  satisfactory MRI assessment for safety monitoring.&#xD;
&#xD;
          9. Has a history or clinical laboratory evidence of moderate congestive heart failure&#xD;
             defined by the New York Heart Association Criteria (Class I to IV).&#xD;
&#xD;
         10. Clinically significant ECG abnormalities at Screening Visit 2, for example:&#xD;
&#xD;
               1. Evidence of atrial fibrillation on ECG or history of atrial fibrillation that is&#xD;
                  not currently controlled&#xD;
&#xD;
               2. QTcF at &gt; 450 ms in males or &gt; 470 ms in females, or low or flat T waves making&#xD;
                  measurement of QT interval unreliable&#xD;
&#xD;
         11. Has a history of new ischemic or congestive cardiovascular event within the 3 months&#xD;
             prior to Visit 3 (Baseline).&#xD;
&#xD;
         12. Has a history of or current major psychiatric illness such as schizophrenia or bipolar&#xD;
             affective disorder.&#xD;
&#xD;
         13. Has a clinician-administered Patient Health Questionnaire (PHQ)-9 score of ≥ 10 or in&#xD;
             the Investigator's opinion, depression of a severity that would impact cognitive&#xD;
             assessments.&#xD;
&#xD;
         14. Subjects with insulin dependent diabetes.&#xD;
&#xD;
         15. Subjects with uncontrolled hypertension defined as:&#xD;
&#xD;
               1. average of 3 systolic blood pressure [SBP]/diastolic blood pressure [DBP]&#xD;
                  readings &gt; 165/100 mmHg at Screening Visit 2 (blood pressure measurements&#xD;
                  exceeding these limits may be repeated as warranted by the Investigator, but&#xD;
                  values must be within the specified limits for the subject to be eligible for the&#xD;
                  study),&#xD;
&#xD;
               2. or persistent SBP/DBP readings &gt; 180/100 mmHg 3 months prior to Baseline (Visit&#xD;
                  3, Day 1) that in the opinion of the Investigator are indicative of chronic&#xD;
                  uncontrolled hypertension.&#xD;
&#xD;
         16. Subjects with orthostatic hypotension, defined as a drop of &gt;20 mmHg systolic blood&#xD;
             pressure upon standing upright from a seated position within 3 minutes, at Screening&#xD;
             Visit 2; testing for orthostatic hypotension may be repeated at Investigator's&#xD;
             discretion if there is reason to believe the condition is temporary after addressing&#xD;
             the temporary cause.&#xD;
&#xD;
         17. At Screening Visit 2, clinically significant:&#xD;
&#xD;
               1. anaemia (haemoglobin &lt; 11 g/dL for males or &lt; 10 g/dL for females)&#xD;
&#xD;
               2. renal disease or insufficiency, including but not limited to a creatinine value&#xD;
                  of &gt; 1.9 mg/dL (&gt; 170 μmol/L)&#xD;
&#xD;
               3. hypothyroidism&#xD;
&#xD;
         18. At Screening Visit 2, laboratory test values (potential to repeat at Investigators&#xD;
             discretion):&#xD;
&#xD;
               1. ALT, AST, total bilirubin, or alkaline phosphatase &gt; 2.5 times the ULN laboratory&#xD;
                  range, or history of severe hepatobiliary disease (e.g., hepatitis B or C, or&#xD;
                  cirrhosis [Childs-Pugh Classes B/C] without enzyme elevation)&#xD;
&#xD;
               2. Fasting triglycerides &gt; 2.5 times the ULN&#xD;
&#xD;
               3. Cholesterol &gt; 240 mg/dL&#xD;
&#xD;
         19. Clinically significant Vitamin B12 deficiency within 12 months prior to Visit 1;&#xD;
             however, subjects on stable replacement therapy for a minimum of 1 month immediately&#xD;
             prior to Visit 1 may be included.&#xD;
&#xD;
         20. The following GI conditions are exclusionary as described below:&#xD;
&#xD;
               1. Inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease), GI&#xD;
                  bleed (upper or lower), or peptic ulcer disease; any of these conditions are&#xD;
                  exclusionary, if active in the past 5 years. Subjects with remote quiescent&#xD;
                  disease, at Investigators discretion (and CER Committee) are not excluded.&#xD;
&#xD;
               2. Subjects with current or a history of (within the last 5 years) any of the&#xD;
                  following conditions are excluded: complicated reflux disease (e.g., Barrett's&#xD;
                  oesophagus, stricture, ulcer, haemorrhage), or severe GERD that, in the opinion&#xD;
                  of the Investigator, is not well-controlled by medication.&#xD;
&#xD;
               3. Irritable bowel syndrome, diverticular disease (e.g., diverticulosis, or&#xD;
                  diverticulitis), or chronic gastritis; any of these conditions are exclusionary&#xD;
                  if there has been an acute event within 1 year prior to Screening Visit 1.&#xD;
&#xD;
         21. Has donated ≥ 2 units of blood within the 1 month prior to Screening Visit 1.&#xD;
&#xD;
         22. Has a history of alcohol or drug abuse within the 6 months prior to Visit 1 or has&#xD;
             tested positive upon urine drug screen at Screening Visit 2.&#xD;
&#xD;
         23. Subject or caregiver is an immediate family member or employee of the clinical site,&#xD;
             Sponsor, or of the Sponsor's agents.&#xD;
&#xD;
         24. Has any current or history of neoplasm or malignancy, other than excised or treated&#xD;
             basal cell carcinoma. The following exceptions may be made after discussion with the&#xD;
             Medical Monitor:&#xD;
&#xD;
               1. Subjects with cancers in remission more than 5 years prior to Screening.&#xD;
&#xD;
               2. Subjects with a history of excised or treated squamous carcinoma of the skin.&#xD;
&#xD;
               3. Subjects with prostate cancer in situ.&#xD;
&#xD;
         25. Subject has a scheduled (or is expected to have scheduled) hospitalisation and/or&#xD;
             surgery during the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Project Manager</last_name>
    <phone>+1 303 999 3700</phone>
    <email>clinical@cerecin.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

